Laura Campbell

Vice President I Clinical Development at Orchard Therapeutics PLC

Laura Campbell began their work experience in 2010 as a Doctor undergoing Foundation Training at Chelsea and Westminster Hospital NHS Foundation Trust. Laura then transitioned into a role as a Surgeon in Core Training at the same hospital from 2012 to 2014. Following that, they served as a Surgical Registrar at NHS before joining GSK as a Medical Advisor for Respiratory in the UK in 2015. Laura moved on to become a Global Medical Affairs Manager at GSK, focusing on Cell & Gene Therapy for Rare Diseases. Laura then worked at Orchard Therapeutics, holding various roles such as Global Medical Director for Primary Immunodeficiencies and Vice President of Clinical Development. During their time at Orchard Therapeutics, they held positions in different areas of medical affairs and clinical development, showcasing their expertise in gene therapy assets and strategy development. After that, they completed Pharmaceutical Medicine Specialist Training at the Faculty of Pharmaceutical Medicine and continued to progress their career in leadership roles within the industry.

Laura Campbell completed their Bachelor of Medicine, Bachelor of Surgery (MB BChir) at the University of Cambridge from 2007 to 2010, with a prior Bachelor's Degree in Natural Sciences also from the University of Cambridge from 2004 to 2007. Laura has continued their education with various certifications in Pharmaceutical Medicine, Drug Safety Surveillance, Clinical Pharmacology, and Clinical Drug Development, among others. Additionally, they have pursued online certificate programs in Genetics and Immunology at Harvard Medical School.

Location

London, United Kingdom

Links

Previous companies


Org chart


Teams


Offices


Orchard Therapeutics PLC

3 followers

Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.


Industries

Employees

201-500

Links